TX-MAVENIR
11.1.2021 14:02:37 CET | Business Wire | Press release
Mavenir , the industry’s only end-to-end Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), has expanded and cloudified its Portfolio by announcing four new solutions: WebScale Platform, AI & Analytics, Multi-Access Edge Computing (MEC) and Digital Enablement Platform, all available today.
With cloud-native applications and technology innovation in the software space for mobile communications, consistent with Mavenir’s DNA, these solutions support the ongoing cloudification of the mobile networks, to enable CSPs to meet the growing data demands on their networks.
Mavenir’s cloud centric approach means moving applications to Commercial Off-The-Shelf (COTS) computing servers and embracing a complete ecosystem with applications in the Cloud (private, hybrid or public), which complement the basic Network Virtualized Functions (NVFs) and bring automation to improve the way operators manage and operate their networks.
In addition, this approach creates more flexibility and agility enabling the introduction of new services not only in the traditional consumer business, but also in the enterprise arena.
Webscale Platform: Suresh Somasundaram, SVP of 5G Cloud Platforms at Mavenir explains, “Mobile networks require digital transformation towards webscale platform technology that utilizes open source, Kubernetes platform as a service (PaaS). While a Kubernetes-based platform (PaaS) provides the foundation for fully automated life cycle management, it is built for mainly IT and enterprise applications and requires additional and specialized functions to support telecom and specifically, mobile workloads. To support those types of workloads, Mavenir has developed a common software extending standard opensource PaaS components to support telco needs for webscale deployment and to provide agile delivery of new applications expanding to Performance, Monitoring, Legal Intercept and Security. Mavenir’s WebScale Platform is the solution to give Mobile Operators the webscale agility of the Internet players.”
AI-powered Analytics : Kuntal Chowdhury, GM, AI & Analytics at Mavenir said, “With the cloudification and automation of the telecom networks, it becomes essential to utilize AI & Analytics solutions in a scalable platform combining real-time and big data analytics based on advanced Machine Learning algorithms. Mavenir’s AI & Analytics platform delivers extensive insights that are mandatory for WebScale network automation, slice management, security and many other use cases defined for the MEC (EdgeAI), RAN intelligence, traffic optimization and security. The AI/ML algorithms are defined with Mavenir’s deep telecom domain expertise, while keeping the interfaces standards-compliant & the platform open for collaborative innovation.”
Multi-access Edge Computing (MEC) : Ashok Khuntia, GM Cloud Packet Computing says, “Delivering low latency and high bandwidth at the edge of the network promises many exciting applications in 5G. Mavenir's optimized low-footprint data processing 5G Core platform enables mission critical MEC applications in the areas of Industrial automation, Augmented Reality/Virtual Reality, Gaming, Video surveillance, Autonomous driving and others. The additional focus on Multi-access Edge Computing (MEC) will accelerate such applications for many different industries and sectors.”
Digital Enablement: Sandeep Singh, GM, Digital Enablement at Mavenir noted, “Mavenir enables Operators and Enterprises to launch innovative value-based services faster to market with lower upfront investments in capital and time. Mavenir’s Digital Enablement Platform unlocks any network data, sources partner data, and serves up a value-added offering enriched through the platform’s flexible business control functions like Partner/Customer Management, Order Journey-Experience builder, Subscription/Usage Billing, Charging and Settlement. With the design focus on ‘adaptability’, the platform provides customers the agility and flexibility to experiment iteratively and deliver enhanced subscriber engagement experiences, ultimately benefitting in increased market reach and customer stickiness through new revenue generating services.”
“With a modern and secure Webscale platform as a foundation for edge computing, state of the art AI-based Analytics and Customer engagement solutions in our portfolio, Mavenir is a partner of choice for Telcos looking to offer new mission critical network edge solutions, transform network operations and business models for new 5G networks. In addition, Enterprises who need cost efficiency and customization in their connectivity and communication solutions will benefit,” said Bejoy Pankajakshan, Mavenir’s Chief Strategy Officer. “With a worldwide installed base and decades of experience in designing ‘Multi-G’ Telco services, Mavenir now offers its customer a path to realize the true potential of 5G through these new technology solutions.”
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom